The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
The entry of entry inhibitors: A fusion of science and medicine
Open accessAbstract
For HIV-1 to enter a cell, its envelope protein (Env) must sequentially engage CD4 and a chemokine coreceptor, triggering conformational changes in Env that ultimately lead to fusion between the viral and host cell membranes. Each step of the virus entry pathway is a potential target for novel antiviral agents termed entry inhibitors. A growing number of entry inhibitors are under clinical development, with one having already been licensed by the Food and Drug Administration. With the emergence of virus strains that are largely resistant to existing reverse transcriptase and protease inhibitors, the development of entry inhibitors comes at an opportune time. Nonetheless, because all entry inhibitors target in some manner the highly variable Env protein of HIV-1, there are likely to be challenges in their efficient application that are unique to this class of drugs. Env density, receptor expression levels, and differences in affinity and receptor presentation are all factors that could influence the clinical response to this promising class of new antiviral agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180
Core Structure of gp41 from the HIV Envelope Glycoprotein
Chan, D. C., Fass, D., Berger, J. M., & Kim, P. S. (1997) · Cell · doi:10.1016/s0092-8674(00)80205-6 · Cited by 1,959
Atomic structure of the ectodomain from HIV-1 gp41
Weissenhorn, W., Dessen, A., Harrison, S. C., Skehel, J. J., & Wiley, D. C. (1997) · Nature · doi:10.1038/387426a0 · Cited by 1,622
The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens
Wyatt, R., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1884 · Cited by 1,598
Wei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569
Kilby, J. M., Hopkins, S., Venetta, T. M., DiMassimo, B., Cloud, G. A., Lee, J. Y., Alldredge, L., Hunter, E., Lambert, D., Bolognesi, D., et al. (1998) · Nature Medicine · doi:10.1038/3293 · Cited by 987
Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America
Lalezari, J. P., Henry, K., O'Hearn, M., Montaner, J. S. G., Piliero, P. J., Trottier, B., Walmsley, S., Cohen, C., Kuritzkes, D. R., Eron, J. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035026 · Cited by 914
A Conserved HIV gp120 Glycoprotein Structure Involved in Chemokine Receptor Binding
Rizzuto, C. D., Wyatt, R., Hernández-Ramos, N., Sun, Y., Kwong, P. D., Hendrickson, W. A., & Sodroski, J. (1998) · Science · doi:10.1126/science.280.5371.1949 · Cited by 812
Diversity Considerations in HIV-1 Vaccine Selection
Gaschen, B., Taylor, J., Yusim, K., Foley, B., Gao, F., Lang, D., Novitsky, V., Haynes, B., Hahn, B. H., Bhattacharya, T., et al. (2002) · Science · doi:10.1126/science.1070441 · Cited by 811
A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity
Baba, M., Nishimura, O., Kanzaki, N., Okamoto, M., Sawada, H., Iizawa, Y., Shiraishi, M., Aramaki, Y., Okonogi, K., Ogawa, Y., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5698 · Cited by 751
CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro
Wu, L., Paxton, W. A., Kassam, N., Ruffing, N., Rottman, J. B., Sullivan, N., Choe, H., Sodroski, J., Newman, W., Koup, R. A., et al. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1681 · Cited by 694
Tyrosine Sulfation of the Amino Terminus of CCR5 Facilitates HIV-1 Entry
Farzan, M., Mirzabekov, T., Kolchinsky, P., Wyatt, R., Cayabyab, M., Gerard, N. P., Gerard, C., Sodroski, J., & Choe, H. (1999) · Cell · doi:10.1016/s0092-8674(00)80577-2 · Cited by 693
Lee, B., Sharron, M., Montaner, L. J., Weissman, D., & Doms, R. W. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5215 · Cited by 579
Self-citationMelikyan, G. B., Markosyan, R. M., Hemmati, H., Delmedico, M. K., Lambert, D. M., & Cohen, F. S. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.413 · Cited by 576
Determinants of Human Immunodeficiency Virus Type 1 Resistance to gp41-Derived Inhibitory Peptides
Rimsky, L. T., Shugars, D. C., & Matthews, T. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.986-993.1998 · Cited by 423
Reeves, J. D., Gallo, S. A., Ahmad, N., Miamidian, J. L., Harvey, P. E., Sharron, M., Pöhlmann, S., Sfakianos, J. N., Derdeyn, C. A., Blumenthal, R., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.252469399 · Cited by 404
Self-citationA small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding
Lin, P.-F., Blair, W., Wang, T., Spicer, T., Guo, Q., Zhou, N., Gong, Y.-F., Wang, H.-G. H., Rose, R., Yamanaka, G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832214100 · Cited by 357
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use
Trkola, A., Kuhmann, S. E., Strizki, J. M., Maxwell, E., Ketas, T., Morgan, T., Pugach, P., Xu, S., Wojcik, L., Tagat, J., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012519099 · Cited by 303
Self-citationStrizki, J. M., Xu, S., Wagner, N. E., Wojcik, L., Liu, J., Hou, Y., Endres, M., Palani, A., Shapiro, S., Clader, J. W., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221375398 · Cited by 299
Self-citationDoms, R. W., & Moore, J. P. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.151.2.f9 · Cited by 296
Self-citationO'Brien, S. J., & Moore, J. P. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17710.x · Cited by 254
Self-citationThe neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
Parren, P. W. H. I., Moore, J. P., Burton, D. R., & Sattentau, Q. J. (1999) · PubMed · Cited by 248
Self-citationGorry, P. R., Taylor, J., Holm, G. H., Mehle, A., Morgan, T., Cayabyab, M., Farzan, M., Wang, H., Bell, J. E., Kunstman, K., et al. (2002) · Journal of Virology · doi:10.1128/jvi.76.12.6277-6292.2002 · Cited by 212
Self-citationKilby, J. M., Lalezari, J. P., Eron, J. J., Carlson, M., Cohen, C., Arduino, R. C., Goodgame, J. C., Gallant, J. E., Volberding, P., Murphy, R. L., et al. (2002) · AIDS Research and Human Retroviruses · doi:10.1089/088922202760072294 · Cited by 198
Mosier, D. E., Picchio, G. R., Gulizia, R. J., Sabbe, R., Poignard, P., Picard, L., Offord, R. E., Thompson, D. A., & Wilken, J. (1999) · Journal of Virology · doi:10.1128/jvi.73.5.3544-3550.1999 · Cited by 182
Edwards, T. G., Wyss, S., Reeves, J. D., Zolla-Pazner, S., Hoxie, J. A., Doms, R. W., & Baribaud, F. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2683-2691.2002 · Cited by 173
Self-citationHIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
Jp, M., & Ho, D. D. (1995) · PubMed · Cited by 171
Chen, C. H., Matthews, T. J., McDanal, C. B., Bolognesi, D. P., & Greenberg, M. L. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3771-3777.1995 · Cited by 169
New targets for inhibitors of HIV-1 replication
Moore, J. P., & Stevenson, M. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036060 · Cited by 167
Self-citationGallo, S. A., Puri, A., & Blumenthal, R. (2001) · Biochemistry · doi:10.1021/bi0155596 · Cited by 132
The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication
de Vreese, K., Kofler-Mongold, V., Leutgeb, C., Weber, V., Vermeire, K., Schacht, S., Anné, J., Clercq, E. D., DATEMA, R., & Werner, G. (1996) · Journal of Virology · doi:10.1128/jvi.70.2.689-696.1996 · Cited by 130
He, Y., Vassell, R. A., Zaitseva, M. B., Nguyen, N. Y., Yang, Z., Weng, Y., & Weiss, C. D. (2003) · Journal of Virology · doi:10.1128/jvi.77.3.1666-1671.2003 · Cited by 130
Multiple nonfunctional alleles of CCR5 are frequent in various human populations
Blanpain, C., Lee, B., Tackoen, M., Puffer, B. A., Boom, A., Libert, F., Sharron, M., Wittamer, V., Vassart, G., Doms, R. W., et al. (2000) · Blood · doi:10.1182/blood.v96.5.1638 · Cited by 118
Self-citationRecent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors
Kazmierski, W. M., Bifulco, N., Yang, H., Boone, L., Deanda, F., Watson, C., & Kenakin, T. (2003) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(03)00161-5 · Cited by 110
Schols, D., Esté, J. A., Cabrera, C., & Clercq, E. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4032-4037.1998 · Cited by 109
Esté, J. A., Cabrera, C., Blanco, J., Gutiérrez, A., Bridger, G. J., Henson, G. W., Clotet, B., Schols, D., & Clercq, E. D. (1999) · Journal of Virology · doi:10.1128/jvi.73.7.5577-5585.1999 · Cited by 107
Baseline Susceptibility of Primary Human Immunodeficiency Virus Type 1 to Entry Inhibitors
Labrosse, B., Labernardière, J., Dam, E., Trouplin, V., Skrabal, K., Clavel, F., & Mammano, F. (2002) · Journal of Virology · doi:10.1128/jvi.77.2.1610-1613.2003 · Cited by 92
Tremblay, C. L., Giguel, F. F., Kollmann, C. S., Guan, Y., Chou, T., Baroudy, B. M., & Hirsch, M. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1336-1339.2002 · Cited by 86
HIV entry inhibitors in clinical development
O'Hara, B., & Olson, W. C. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00196-0 · Cited by 33
Cited by
Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme
White, J. M., Delos, S. E., Brecher, M., & Schornberg, K. (2008) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230802058320 · Cited by 892
Virus membrane-fusion proteins: more than one way to make a hairpin
Kielian, M., & Rey, F. A. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1326 · Cited by 570
Moore, J. P., Kitchen, S. G., Pugach, P., & Zack, J. A. (2004) · AIDS Research and Human Retroviruses · doi:10.1089/088922204322749567 · Cited by 494
Self-citationSmall Molecules Blocking the Entry of Severe Acute Respiratory Syndrome Coronavirus into Host Cells
Yi, L., Li, Z., Yuan, K., Qu, X., Chen, J., Wang, G., Zhang, H., Luo, H., Zhu, L., Jiang, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.20.11334-11339.2004 · Cited by 485
Peptides Containing β-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry
Cabrele, C., Martinek, T. A., Reiser, O., & Berlicki, Ł. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5010896 · Cited by 368
Metadata
- Authors
- Moore, J. P., & Doms, R. W.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-09-05
- Volume
- 100
- Issue
- 19
- Pages
- 10598-10602
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2064492827
- Cited by
- 278
- References
- 40
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.